jRCT2031260334招募中不适用
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of secutrelvir in participants with COVID-19 (COVID-19)
未提供0 个研究点目标入组 1,200 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 12age old over 至 75age old not（—）
- 性别
- All
入选标准
- •Must be 12 to < 18 years of age with a body weight >= 40 kg, or >= 18 and < 75 years of age regardless of body weight.
- •Must have >= 1 of the following COVID-19 symptoms, present within 24 hours prior to randomization.
- •Confirmed SARS-CoV-2 infection as determined by any SARS-CoV-2 test from any respiratory tract specimen, collected <= 48 hours prior to randomization.
- •Must be randomized within 48 hours of COVID-19 symptom onset.
排除标准
- •Documented respiratory infection (eg, influenza, respiratory syncytial virus infection) other than COVID-19 within 14 days prior to the screening visit.
- •Known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy).
- •Suspected or confirmed COVID-19 outside of the current episode within 3 months of randomization.
研究者
相似试验
尚未招募
不适用
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to MASH (NEBULA 1)Compensated cirrhosis due to metabolic dysfunction-associated steatohepatitisjRCT2041260084103
招募中
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features,in Bipolar-I Disorder TakingLithium, Valproate, or Lamotrigine (CN0120046)Bipolar-I DisorderjRCT204125017027
招募中
不适用
A phase 3 study of TS-172 in hyperphosphatemia patients on hemodialysis with phosphate bindersHyperphosphatemiajRCT2031250548100
招募中
不适用
A Phase 2 study of naldemedine in participants with constipation associated with Parkinson's diseasejRCT203126006040
招募中
不适用
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (J3R-MC-YDAG)Obesity
OverweightjRCT20312508011,980